The Administrative/Clinical Trials Core C will serve to facilitate communication and manage interactions among SPORE investigators, and between SPORE members and other research and administrative units at Moffitt and with the NCI. Core C will provide organizational and financial oversight of all 4 projects, 3 cores and the Developmental Research and Career Development Programs, as well as provide for clinical trials coordination and data management support for all four melanoma trials integral to the Moffitt Skin SPORE. It includes support for a data manager and a clinical trials coordinator who will be critical to the performance of the trials of the SPORE. Administrative Core C also includes support for an administrator and an assistant who will have overall day to day responsibility for the successful carrying out of all SPORE activities, including financial oversight and coordination, publicity and record keeping, and critically will coordinate the integration of the regulatory and oversight activities in the running of the Moffitt Skin SPORE. This will assure that all administrative requirements for successful completion of the overall SPORE goals and the requirements of the NCI and all other regulatory bodies including Moffitt, USF, the State of Florida and the FDA are met. Importantly, the Administrative Core C will coordinate the dissemination of information about the Developmental Research and Career Development Programs and oversee the reviews of those projects as well as the progress reports required. It will also provide for yearly retreats and meetings of the internal lAC and external EAB meetings. It will provide the logistic capability necessary for development and support of all projects, cores, and programs, and it will integrate patient advocacy as a vital component of laboratory and clinical skin cancer research. Administrative Core C includes personnel who are not specifically listed or budgeted within individual research projects. However, these personnel, who are listed in the Budget Justification section are vital to the successful function of the Moffitt Skin SPORE, and are required across all projects.

Public Health Relevance

Administrative Core C of the Moffitt Skin SPORE will be responsible for the successful carrying out of all SPORE activities related to financial oversight and coordination, publicity and record keeping in Projects 1, 2, 3 and 4. The core will provide for integration of the regulatory and oversight activities of all four melanoma trials in Projects 1, 2, and 3 and ensure that the peer review, awarding and oversight processes of the Career Development and Developmental Research Programs are properly carried out.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Specialized Center (P50)
Project #
Application #
Study Section
Special Emphasis Panel (ZCA1-RPRB-M (M1))
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
H. Lee Moffitt Cancer Center & Research Institute
United States
Zip Code
Rebecca, Vito W; Wood, Elizabeth; Fedorenko, Inna V et al. (2014) Evaluating melanoma drug response and therapeutic escape with quantitative proteomics. Mol Cell Proteomics 13:1844-54
Kim, Sungjune; Ramakrishnan, Rupal; Lavilla-Alonso, Sergio et al. (2014) Radiation-induced autophagy potentiates immunotherapy of cancer via up-regulation of mannose 6-phosphate receptor on tumor cells in mice. Cancer Immunol Immunother 63:1009-21
Smyth, Tomoko; Paraiso, Kim H T; Hearn, Keisha et al. (2014) Inhibition of HSP90 by AT13387 delays the emergence of resistance to BRAF inhibitors and overcomes resistance to dual BRAF and MEK inhibition in melanoma models. Mol Cancer Ther 13:2793-804
Haarberg, H Eirik; Smalley, Keiran S M (2014) Resistance to Raf inhibition in cancer. Drug Discov Today Technol 11:27-32
Rebecca, Vito W; Smalley, Keiran S M (2014) Change or die: targeting adaptive signaling to kinase inhibition in cancer cells. Biochem Pharmacol 91:417-25
Johnson, Douglas B; Smalley, Keiran S M; Sosman, Jeffrey A (2014) Molecular pathways: targeting NRAS in melanoma and acute myelogenous leukemia. Clin Cancer Res 20:4186-92
Rebecca, Vito W; Alicea, Gretchen M; Paraiso, Kim H T et al. (2014) Vertical inhibition of the MAPK pathway enhances therapeutic responses in NRAS-mutant melanoma. Pigment Cell Melanoma Res 27:1154-8
Cheng, Fengdong; Lienlaf, Maritza; Perez-Villarroel, Patricio et al. (2014) Divergent roles of histone deacetylase 6 (HDAC6) and histone deacetylase 11 (HDAC11) on the transcriptional regulation of IL10 in antigen presenting cells. Mol Immunol 60:44-53
Rebecca, Vito W; Massaro, Renato R; Fedorenko, Inna V et al. (2014) Inhibition of autophagy enhances the effects of the AKT inhibitor MK-2206 when combined with paclitaxel and carboplatin in BRAF wild-type melanoma. Pigment Cell Melanoma Res 27:465-78
Fedorenko, Inna V; Fang, Bin; Koomen, John M et al. (2014) Amuvatinib has cytotoxic effects against NRAS-mutant melanoma but not BRAF-mutant melanoma. Melanoma Res 24:448-53